|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: EMA & FDA (2014)) |
IUPAC Name ![]() |
| 4-[(E)-2-[4-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]phenyl]ethenyl]-N-methylaniline |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9184 | florbetaben (18F) |
Synonyms ![]() |
|
| Names | References |
| [18F]BAY 94-9172 | 1 |
| AV-1 | 2 |
| BAY 94-9172 | 2 |
| Neuraceq® | |
Database Links ![]() |
|
| CAS Registry No. | 902143-01-5 (source: Scifinder) |
| PubChem CID | 11501341 |
| Search Google for chemical match using the InChIKey | NCWZOASIUQVOFA-FWZJPQCDSA-N |
| Search Google for chemicals with the same backbone | NCWZOASIUQVOFA |
| Search PubMed clinical trials | florbetaben |
| Search PubMed titles | florbetaben |
| Search PubMed titles/abstracts | florbetaben |
| Wikipedia | Florbetaben_(18F) |
| Comments |
| Florbetaben F18 is the third PET (positron-emission tomography) reagent approved to identify amyloid-β (Aβ) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) [1]. Flutemetamol and florbetapir are the two other PET reagents approved for Aβ detection. These diagnostic tools allow direct and non-invasive in vivo visualisation and quantification of Aβ. |